会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明公开
    • Preparation of optically active alpha-arylalkanoic acids and precursors thereof
    • 一种制备光学活性的α-芳基链烷酸和它们的前体的过程。
    • EP0110671A1
    • 1984-06-13
    • EP83307158.2
    • 1983-11-23
    • SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED
    • Erickson, Gary W.
    • C07C51/353C07C59/64C07C57/30C07C57/38C07C57/40C07C57/58C07C69/736C07C69/612C07C69/616
    • C07C51/353C07C51/347C07C57/38C07C59/64C07C57/30C07C57/40C07C57/58
    • This invention concerns a process of preparing optically active a-arylalkanoic acids useful as pharmaceutical (e.g., anti-inflammatory) agents, and their precursors. These a-arylalkanoic acids, esters, amides, nitriles, oxazolines and metal salts are stereoselectively prepared by forming the metal or metal halide of the corresponding acid, ester, amide, oxazoline, nitrile, or metal salt and treating the compound so prepared with an aryl halide in the presence of a chiral (optically active) transition metal catalyst, optionally in the presence of a dipolar aprotic solvent or mixtures thereof, for a time sufficient to form the corresponding optically active a-arylalkanoic acid, ester, amide, nitrile, oxazoline or metal salt, and optionally concomitantly or sequentially hydrolyzing any ester, amide, nitrile, oxazoline or metal salt formed to the corresponding optically active α-arylalkanoic acid. The process optionally further includes removal of halogen atom from the aromatic portion or methylation of the aryl hydroxyl portion of the a-arylalkanoic acid, as well as subsequent formation of the pharmaceutically acceptable salts and esters of the optically active a-arylalkanoic acid.
    • 本发明涉及制备作为药物(例如,抗炎)剂,及其前体的有用的光学活性的α-氨基酸-arylalkanoic的处理。 这些α--arylalkanoic酸,酯,酰胺,腈,恶唑啉和金属盐立体选择性地通过形成相应的酸的金属或金属卤化物,酯,酰胺,恶唑啉,腈,或金属盐和处理该化合物,从而与制备制备 芳基卤化物在手性(光学活性)的过渡金属催化剂的存在下,任选在偶极非质子溶剂或存在它们的混合物,足够长的时间以形成所述光学活性的α-CORRESPONDING -arylalkanoic酸,酯,酰胺,腈, 恶唑啉或金属的盐,以及任选地同时或相继水解任何酯,酰胺,腈,在对应于所述光学活性的α--arylalkanoic酸恶唑啉或金属盐。 的方法可选地还包括由芳族部分或α-arylalkanoic酸的羟基芳基部分的甲基化去除卤素原子的,以及光学活性的α--arylalkanoic酸的药学上可接受的盐和酯的后续形成。